Soluliamfetor for the treatment of cognitive impairment in subjects with cognitive impairment associated with obstructive sleep apnea and excessive daytime sleepiness.

Abstract

The present invention relates to a carbamoylphenylalaninol compound and a method of using the same for enhancing one or more cognitive functions in subjects having cognitive impairments associated with obstructive sleep apnea and excessive daytime sleepiness, and for treating one or more cognitive impairments in such subjects.

Claims

1. A method for enhancing one or more cognitive functions, comprising a therapeutically effective dose of Formula II for subjects with cognitive impairment associated with obstructive sleep apnea and excessive daytime sleepiness. 【Chemistry 1】 A method comprising administering a compound or a pharmaceutically acceptable salt thereof to thereby enhance one or more cognitive impairments in the subject.

2. The compound is of formula I 【Chemistry 2】 The method according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1, wherein the compound is the hydrochloride salt of the compound.

4. The method according to claim 1, wherein the compound is administered orally.

5. The method according to claim 1, wherein one or more cognitive functions are selected from executive function, memory, and learning.

6. The method according to claim 1, wherein the cognitive function is an executive function.

7. The method according to claim 1, wherein the cognitive function is memory.

8. The method according to claim 1, wherein the cognitive function is learning.

9. The method according to claim 1, wherein the one or more cognitive functions are selected from working memory, cognitive flexibility, and response inhibition.

10. The method according to claim 1, wherein the compound is present in a pharmaceutical formulation containing a pharmaceutically acceptable carrier.

11. The method according to claim 1, further comprising administering a nootropic drug to a subject in need thereof.

12. A method for treating one or more cognitive impairments in a subject having cognitive impairments associated with obstructive sleep apnea and excessive daytime sleepiness, wherein the therapeutic effective dose is given by formula II 【Transformation 3】 A method comprising administering a compound or a pharmaceutically acceptable salt thereof to a subject having one or more cognitive impairments, thereby treating one or more cognitive impairments in the subject.

13. The aforementioned compound is, Formula I 【Chemistry 4】 The method according to claim 12, wherein the compound is or a pharmaceutically acceptable salt thereof.

14. The method according to claim 12, wherein the compound is the hydrochloride salt of the compound.

15. The method according to claim 12, wherein the subject is identified as having Alzheimer's disease, schizophrenia, autism, or obsessive-compulsive disorder.

16. The method according to claim 12, wherein the cognitive impairment is selected from executive function impairment, learning disability, and memory impairment.

17. The method according to claim 16, wherein the cognitive impairment is an executive function disorder.

18. The method according to claim 16, wherein the cognitive impairment is a learning disability.

19. The method according to claim 16, wherein the cognitive impairment is memory impairment.

20. The method according to claim 12, wherein the cognitive impairment is selected from cognitive flexibility impairment, working memory impairment, and response inhibition impairment.

21. The method according to claim 20, wherein the cognitive impairment is a cognitive flexibility disorder.

22. The method according to claim 20, wherein the cognitive impairment is a working memory disorder.

23. The method according to claim 20, wherein the cognitive impairment is a response inhibition disorder.

24. The method according to claim 12, wherein the compound is present in a pharmaceutical formulation containing a pharmaceutically acceptable carrier.

25. The method according to claim 12, further comprising administering a nootropic drug to the subject having one or more cognitive impairments.

26. A method for delaying or slowing the increase of one or more cognitive impairments in subjects having cognitive impairments associated with obstructive sleep apnea and excessive daytime sleepiness, comprising: a therapeutically effective amount of Formula II in subjects having or at risk of having the one or more cognitive impairments. 【Transformation 5】 A method comprising administering a compound or a pharmaceutically acceptable salt thereof to treat one or more cognitive impairments in the subject.

27. The aforementioned compound is, Formula I 【Transformation 6】 The method according to claim 26, wherein the compound is a pharmaceutically acceptable salt thereof.

28. The method according to claim 26, wherein the compound is the hydrochloride salt of the compound.

29. The method according to claim 26, wherein the subject is identified as having Alzheimer's disease, schizophrenia, autism, or obsessive-compulsive disorder.

30. The method according to claim 26, wherein the cognitive impairment is selected from executive function impairment, learning impairment and memory impairment.

31. The method according to claim 30, wherein the cognitive impairment is an executive function disorder.

32. The method according to claim 30, wherein the cognitive impairment is a learning disability.

33. The method according to claim 30, wherein the cognitive impairment is memory impairment.

34. The method according to claim 26, wherein the cognitive impairment is selected from cognitive flexibility impairment, working memory impairment, and response inhibition impairment.

35. The method according to claim 34, wherein the cognitive impairment is a cognitive flexibility disorder.

36. The method according to claim 34, wherein the cognitive impairment is a working memory disorder.

37. The method according to claim 34, wherein the cognitive impairment is a response inhibition disorder.

38. The method according to claim 26, wherein the compound is present in a pharmaceutical formulation containing a pharmaceutically acceptable carrier.

39. The method according to claim 26, further comprising administering a nootropic drug to the subject having one or more cognitive impairments.

Images